WO2018017864A3 - Pvrig-binding agents and uses thereof - Google Patents

Pvrig-binding agents and uses thereof Download PDF

Info

Publication number
WO2018017864A3
WO2018017864A3 PCT/US2017/043128 US2017043128W WO2018017864A3 WO 2018017864 A3 WO2018017864 A3 WO 2018017864A3 US 2017043128 W US2017043128 W US 2017043128W WO 2018017864 A3 WO2018017864 A3 WO 2018017864A3
Authority
WO
WIPO (PCT)
Prior art keywords
pvrig
agents
binding agents
disclosed
antibodies
Prior art date
Application number
PCT/US2017/043128
Other languages
French (fr)
Other versions
WO2018017864A2 (en
Inventor
Austin L. Gurney
Xie MING-HONG
Original Assignee
Oncomed Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals, Inc. filed Critical Oncomed Pharmaceuticals, Inc.
Publication of WO2018017864A2 publication Critical patent/WO2018017864A2/en
Publication of WO2018017864A3 publication Critical patent/WO2018017864A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Agents that specifically bind PVRIG are disclosed. The PVRIG-binding agents may include polypeptides, antibodies, bispecific agents, and/or heterodimeric molecules. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.
PCT/US2017/043128 2016-07-20 2017-07-20 Pvrig-binding agents and uses thereof WO2018017864A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364639P 2016-07-20 2016-07-20
US62/364,639 2016-07-20

Publications (2)

Publication Number Publication Date
WO2018017864A2 WO2018017864A2 (en) 2018-01-25
WO2018017864A3 true WO2018017864A3 (en) 2018-03-01

Family

ID=60996057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/043128 WO2018017864A2 (en) 2016-07-20 2017-07-20 Pvrig-binding agents and uses thereof

Country Status (1)

Country Link
WO (1) WO2018017864A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107580500B (en) 2015-02-19 2023-05-30 康姆普根有限公司 anti-PVRIG antibodies and methods of use
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3617232A1 (en) 2016-08-17 2020-03-04 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
KR102376863B1 (en) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. mesothelin binding protein
US11225523B2 (en) 2017-06-01 2022-01-18 Compugen Ltd. Triple combination antibody therapies
WO2019232484A1 (en) 2018-06-01 2019-12-05 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
AU2019306628A1 (en) * 2018-07-20 2021-02-11 Surface Oncology, Inc. Anti-CD112R compositions and methods
JP7425049B2 (en) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． DLL3 binding protein and method of use
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021113831A1 (en) 2019-12-05 2021-06-10 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022165275A2 (en) 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
WO2022165266A1 (en) 2021-01-28 2022-08-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
CN114907479A (en) * 2021-02-09 2022-08-16 上海君实生物医药科技股份有限公司 anti-CD 112R antibodies and uses thereof
AU2022219681A1 (en) 2021-02-11 2023-09-21 Nectin Therapeutics Ltd. Antibodies against cd112r and uses thereof
CN115925917A (en) * 2021-03-08 2023-04-07 合肥天港免疫药物有限公司 anti-PVRIG protein antibodies or antibody fragments and uses thereof
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CA3227972A1 (en) * 2021-07-30 2023-02-02 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-pvrig/anti-tigit bispecific antibodies and applications thereof
CN117858903A (en) * 2021-09-15 2024-04-09 江苏恒瑞医药股份有限公司 Pharmaceutical composition containing anti-PVRIG/TIGIT bispecific antibody
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2024026496A1 (en) 2022-07-28 2024-02-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253233A1 (en) * 2001-04-06 2004-12-16 Del Rio Cristina Mateo De Acosta Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
US20090258013A1 (en) * 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US20100129380A1 (en) * 2007-04-18 2010-05-27 Mckenzie Andrew Neil James Antibodies Against IL-25
US20110250195A1 (en) * 2008-09-30 2011-10-13 David John Matthews Antibodies Against IL-25
US20110250203A1 (en) * 2008-08-29 2011-10-13 Symphogen A/S Anti-cd5 antibodies
US20130156767A1 (en) * 2005-08-19 2013-06-20 Wyeth Llc Method for treating cachexia using antagonist antibodies against gdf-8
US20140056890A1 (en) * 2012-06-06 2014-02-27 Oncomed Pharmaceuticals, Inc. Binding Agents That Modulate the Hippo Pathway and Uses Thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253233A1 (en) * 2001-04-06 2004-12-16 Del Rio Cristina Mateo De Acosta Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
US20130156767A1 (en) * 2005-08-19 2013-06-20 Wyeth Llc Method for treating cachexia using antagonist antibodies against gdf-8
US20100129380A1 (en) * 2007-04-18 2010-05-27 Mckenzie Andrew Neil James Antibodies Against IL-25
US20090258013A1 (en) * 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US20110250203A1 (en) * 2008-08-29 2011-10-13 Symphogen A/S Anti-cd5 antibodies
US20110250195A1 (en) * 2008-09-30 2011-10-13 David John Matthews Antibodies Against IL-25
US20140056890A1 (en) * 2012-06-06 2014-02-27 Oncomed Pharmaceuticals, Inc. Binding Agents That Modulate the Hippo Pathway and Uses Thereof

Also Published As

Publication number Publication date
WO2018017864A2 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
WO2016191643A3 (en) Tigit-binding agents and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
WO2017184619A3 (en) Agonistic antibodies that bind human cd40 and uses thereof
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
WO2018013818A3 (en) Antibodies against tim3 and uses thereof
WO2017136820A3 (en) Fabs-in-tandem immunoglobulin and uses thereof
WO2018089508A3 (en) Anti-cd47 antibodies
EA201890285A1 (en) ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
WO2017152085A8 (en) Combination therapy with anti-cd73 antibodies
WO2018031490A3 (en) Anti-ox40 binding proteins
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
WO2016207273A3 (en) Multispecific antigen binding proteins
WO2015112886A3 (en) Binding proteins and methods of use thereof
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
WO2015197598A3 (en) Multispecific antigen binding proteins
WO2015197823A3 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
WO2017136659A3 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
WO2016205531A3 (en) Anti-her2 antibodies and methods of use
WO2017015619A8 (en) Antibodies to coagulation factor xia and uses thereof
WO2017106684A3 (en) Antibodies specifically binding hla-dr and their uses
WO2015164392A3 (en) Novel antii-rnf43 antibodies and methods of use
WO2017049038A3 (en) Anti-cd115 antibodies
WO2017214170A3 (en) Baff-r antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17831888

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17831888

Country of ref document: EP

Kind code of ref document: A2